ChatGPT: Will it revolutionise cancer patient information? Part 1

Pinterest LinkedIn Tumblr +

What is ChatGPT? Will it revolutionise the way patients find healthcare information? How does it compare to ‘Dr Google’s’ responses? Does it provide accurate and referenced information? What are the benefits and risks of this emerging technology?

Join our Host Rachael Babin in the first of two podcasts exploring the fascinating new world of artificial intelligence, chatbots and ChatGPT.

Rachael is joined by Ganessan Kichenadasse and Ashley Hopkins to discuss their paper on the role of ChatGPT in Revolutionising Cancer Patient Information.

Papers and Resources:

Hopkins AM, Logan JM, Kichenadasse G, Sorich MJ. Artificial intelligence chatbots will revolutionize how cancer patients access information: ChatGPT represents a paradigm-shift. JNCI Cancer Spectr. 2023 Mar 1;7(2):pkad010. Access online here.

Lee, P, et al. Benefits, Limits, and Risks of GPT-4 as an AI Chatbot for Medicine. N Engl J Med 2023; 388:1233-1239. Access online here.

Ayers JWPoliak ADredze M, et al. Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum. JAMA Intern Med. Published online April 28, 2023. Access online here.



Center for Humane Technology

The Verge

Guests and Host:

Ashley Hopkins

Ashley Hopkins is a NHMRC Investigator, Chair of the COSA Epidemiology Group, and leader of the Clinical Cancer Epidemiology Lab at Flinders University. With a diverse background in pharmacy, pharmacometrics, biostatistics, and machine learning, his research focuses on harnessing clinical data and advanced statistical techniques to facilitate the selection of the right medicine for the right patient, and to provide accurate information to patients in a manner that enables shared decision-making.

Connect with the Precision Medicine Group at Flinders on Twitter: @pmg_flinders

Ganessan Kichenadasse

Dr Kichenadasse is an Oncologist and a Pharmacologist with special interest in the management of variety of cancers such as brain, gynaecological, genitourinary (bladder, kidney, prostate), sarcomas, breast, thyroid cancers, cancer of unknown primary and other rare cancers.

His other passion is conduct and design of all phases of clinical trials for cancer therapies with a focus on early phase (first in human) drug trials. He is an active member of several national and international cancer and pharmacology professional associations.

He holds multiple leadership roles within South Australian Neurological Tumour Bank; state-wide clinical cancer network and SA health cancer drug committee. He is an active member of the management committee of COGNO, and a long-term research committee member for ANZGOG.

Rachael Babin

Rachael Babin is Host of The Oncology Podcast, Editor-in-Chief of The Oncology Newsletter,  and Publisher of Oncology News Australia and The Oncology Network.

With a background in oncology communications and academic publishing, Rachael is happiest sitting behind the mic chatting to interesting people about the impact their work makes in oncology.

Connect on Twitter: @OncologyNewsAus


About Author

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.